GlassScriptPhysician profile
Andrea Teague
NPI 1427292812
$29,629.36
in general payments reported to CMS, 2019-2025
70 companies · $8,507 in 2025
The $8,507 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $1,358 · 2021: $1,804 · 2022: $5,609 · 2023: $2,961 · 2024: $8,339 · 2025: $8,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $9,135 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,427.50 |
| Food and Beverage | $9,134.50 |
| Education | $245.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,915.78 | 2019-2025 | Lynparza, Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $5,350.26 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Janssen Scientific Affairs, LLC | $2,835.37 | 2022-2025 | Darzalex, Rybrevant, Carvykti |
| Stemline Therapeutics INC. | $1,319.72 | 2023-2025 | Orserdu |
| Novartis Pharmaceuticals Corporation | $1,036.94 | 2019-2025 | |
| Seagen INC. | $886.33 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Janssen Biotech, INC. | $861.11 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Exelixis INC. | $754.87 | 2019-2025 | Cabometyx |
| Pfizer INC. | $629.72 | 2019-2025 | |
| Amgen INC. | $569.17 | 2019-2025 | Kyprolis, Imdelltra (Amg757), Blincyto |
| Incyte Corporation | $561.21 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Merck Sharp & Dohme LLC | $504.73 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $489.77 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Gilead Sciences, INC. | $426.78 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $425.66 | 2019-2025 | Polivy, Venclexta, Phesgo |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $410.09 | 2019-2025 | |
| Celgene Corporation | $337.47 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Daiichi Sankyo INC. | $311.14 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Jazz Pharmaceuticals INC. | $308.54 | 2020-2025 | |
| Abbvie INC. | $266.48 | 2020-2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $246.21 | 2020-2025 | |
| Puma Biotechnology, INC. | $240.46 | 2019-2024 | |
| Beigene USA, INC. | $239.02 | 2021-2025 | Brukinsa, Tevimbra |
| Eisai INC. | $234.28 | 2020-2025 | |
| Kite Pharma, INC. | $215.76 | 2020-2025 | Yescarta |
| Adaptive Biotechnologies Corporation | $211.98 | 2022-2025 | Clonoseq |
| Mirati Therapeutics, INC. | $203.85 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $192.91 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.41 | 2021-2025 | Ninlaro, Alunbrig, Iclusig |
| Emd Serono, INC. | $169.28 | 2019-2025 | Bavencio |
| Array Biopharma INC | $158.19 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Taiho Oncology, INC. | $156.16 | 2019-2023 | |
| Blueprint Medicines Corporation | $154.59 | 2021-2025 | Ayvakit |
| Karyopharm Therapeutics INC. | $146.54 | 2020-2025 | Xpovio |
| Cti Biopharma Corp. | $138.56 | 2022-2023 | Vonjo |
| Novocure INC. | $130.79 | 2025 | Optune Gio |
| Rigel Pharmaceuticals, INC. | $114.49 | 2019-2024 | Rezlidhia, Tavalisse |
| Caris Mpi, INC. | $112.65 | 2025 | Mi Cancer Seek |
| Tersera Therapeutics LLC | $96.32 | 2024-2025 | Zoladex |
| Glaxosmithkline, LLC. | $96.18 | 2021-2025 | Ojjaara |
| Pharmaessentia USA Corporation | $88.55 | 2022-2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $84.23 | 2022-2025 | Libtayo |
| Tempus Ai, INC | $74.31 | 2024-2025 | Xt Cdx |
| Pharmacosmos Therapeutics INC. | $69.81 | 2023-2024 | Monoferric |
| Sobi, INC | $58.81 | 2024-2025 | |
| Eusa Pharma (US) LLC | $58.33 | 2019-2022 | |
| Astellas Pharma US INC | $52.27 | 2019-2025 | Xtandi |
| G1 Therapeutics, INC. | $50.45 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $47.35 | 2019-2025 | Rybrevant |
| Genmab U.S., INC. | $46.36 | 2024 | Epkinly |
| Kyowa Kirin, INC. | $45.43 | 2020-2023 | Poteligeo |
| Iovance Biotherapeutics, INC. | $40.17 | 2025 | Amtagvi |
| Alexion Pharmaceuticals, INC. | $39.36 | 2022-2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.61 | 2019 | |
| Menarini Silicon Biosystems, INC. | $27.38 | 2025 | |
| Deciphera Pharmaceuticals INC. | $23.65 | 2023 | Qinlock |
| Agios Pharmaceuticals, INC. | $21.74 | 2024 | |
| Sumitomo Pharma America, INC. | $18.07 | 2023 | Orgovyx |
| Acrotech Biopharma INC. | $17.71 | 2023 | Beleodaq |
| Sirtex Medical INC | $17.24 | 2023 | Sir-Spheres Microspheres |
| Heron Therapeutics, INC. | $15.20 | 2022 | |
| Immunocore Limited | $15.07 | 2025 | Kimmtrak |
| Myovant Sciences INC. | $14.73 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $13.79 | 2023 | Imbruvica |
| Mylan Institutional INC. | $12.99 | 2022 | |
| Dova Pharmaceuticals | $11.98 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Teague listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.